Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

US False Claims Act

Shire Basingstoke

Shire drawn into Luxembourg tax haven exposé

Firm is one of 340 companies identified in report by ICIJ

- PMLiVE

AbbVie is not looking at another big acquisition, says CEO

Unlikely to consider another deal on the scale of failed Shire merger

The pharma business environment in the US

Tighter regulations, more pricing controls and increased international competition will drive market improvements

- PMLiVE

AbbVie and Shire bring merger plans to a close

Blames tax changes in the US

- PMLiVE

AbbVie board recommends dropping Shire deal

Tells stakeholders to vote against merger in light of new rules on corporate tax

- PMLiVE

AbbVie rethinks Shire merger in light of US tax crackdown

Follows action to discourage 'inversion deals' aimed at reducing corporate tax rates

Shire Basingstoke

Shire reaches $56.5m US marketing malpractice settlement

Justice Department agreement covers activities for drugs including Adderall

- PMLiVE

US clamps down on tax inversion deals

Will make it harder for companies to dodge taxes overseas

- PMLiVE

US talks tough on ‘unpatriotic’ tax inversion deals

Treasury looks to 'meaningfully reduce' tax benefits of such manoeuvres

- PMLiVE

It’s on: Shire and AbbVie agree £32bn takeover

Companies agree deal that is set to cut US pharma company’s corporate tax bill

- PMLiVE

AbbVie coaxes Shire into discussions with sweetened offer

Raises takeover bid to $53bn

- PMLiVE

AbbVie raises Shire bid to £30bn

Latest offer is company’s fourth attempt at takeover

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links